Welton Leadership

Welton management team has over 120 years of combined drug development experience.

ART TIPTON, PH.D.
ART TIPTON, PH.D.
EXECUTIVE CHAIRMAN
  • Former President and CEO of Southern Research Institute
  • Former SVP and GM Evonik Birmingham, Global Drug Delivery
  • Former President of the Controlled Release Society
KEVIN SILL, PH.D.
KEVIN SILL, PH.D.
FOUNDER AND CEO
  • Founder and President of Tyndall Formulation Services
  • Co-Inventor: Apisolex™ and SURPAX™ Technologies
  • Oversaw 3 IND programs as former company CEO
BRAD SULLIVAN, PH.D.
BRAD SULLIVAN, PH.D.
FOUNDER AND COO
  • Founder and Vice President of Tyndall Formulation Services
  • Co-Inventor: Apisolex™ and SURPAX™ Technologies
  • USPTO patent agent: drafted and prosecuted Apisolex™ and SURPAX™ patents.
WILL SPRAGUE, CPA
WILL SPRAGUE, CPA
CHIEF FINANCIAL OFFICER
  • Founding Partner at Adventum
  • Former Controller for TampaBay Buccaneers
DAVID LIN, PH.D.
DAVID LIN, PH.D.
WELTON STRATEGIC ADVISOR
  • President of TS Pharma
  • Former Division Director at FDA/CDER